Submission Deadline
19 Apr 2024 (Vol 47 , Iss 04 )

Upcoming Publication
30 Apr 2024 (Vol 47 , Iss 04 )

Journal ID : TMJ-08-12-2021-10855
Download [This article belongs to Volume - 44, Issue - 06]
Total View : 402

Title : Clinicopathological Characteristics of Subcutaneous Panniculitis-like T-cell Lymphoma: An article review

Abstract :

Subcutaneous Panniculitis-like T-cell lymphoma (SPTCL) is a rare malignancy and difficult to diagnose. The clinical and histopathological characteristics of SPTCL overlap with infectious, autoimmune, and aggressive malignancies so that they often miss provisional diagnosis and misdiagnosis. A structured scientific study of the clinicopathological characteristics is needed to increase the clinician's knowledge as consideration for diagnosis. This review aimed to describe the clinicopathological characteristic of patients with SPTCL. This study used a literature review approach which was searched using Pubmed, EBSCO, and Science Direct with the keyword ‘Subcutaneous Panniculitis-like T-cell Lymphoma. The articles were selected based on the inclusion and exclusion criteria set by the researcher. 50 cases obtained from this study indicate that cases of SPTCL occur at a median age of 28.5 years and are dominated by women. Clinicopathological characteristics studies are very helpful in the diagnosis of SPTCL. The clinical characteristics of SPTCL lesions vary, namely in the form of plaque, erythema edema, and mostly nodules on the trunk, extremities, or head. The most common lesion is a predilection nodule on the trunk. Systemic symptoms most commonly include fever and extracutaneous involvement in the form of lymphadenopathy, hepatosplenomegaly, bone marrow involvement, and hemophagocytic syndrome. The histopathological characteristics of adipocyte rimming, karyorrhexis, and fat necrosis with small-medium sized atypical T-cell infiltration and also a lobular pattern. The immunohistochemistry characteristics of SPTCL are CD3+, CD8+, CD56-, TIA-1+, Beta-F1+, Granzyme B+, and Ki-67 >30%. as well as the CD3+, CD8+, CD56-, Beta F1+, Granzyme B+ and Ki-67 levels >30%.

Full article